ArticleBioscience reports2026
Expression, purification, and in vitro characterization of the carboxylesterase CEST-9.2 from Caenorhabditis elegans.
Article in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The nematode Caenorhabditis elegans biosynthesizes the ascarosides, a large, modular family of pheromones that are used in chemical communication. A number of carboxylesterase domain-containing (CEST) enzymes are responsible for decorating the glycolipid core of the ascarosides with a variety of modifications. However, these enzymes, which are homologous to human carboxylesterases and acetylcholinesterase, have not been characterized biochemically, and thus the mechanism whereby they attach different modifications to the ascarosides is unknown. Here, we report the expression, purification, and biochemical characterization of a soluble CEST enzyme for the first time. In this study, we focused on CEST-9.2, which is responsible for making (E)-2-methyl-2-butenoyl (MB)-modified ascarosides. We identified candidate substrates for the enzyme, and we successfully expressed a truncated version of CEST-9.2, which is lacking the transmembrane domain, in several expression systems, including Escherichia coli, Pichia pastoris, and Spodoptera frugiperda Sf9 cells. The purified CEST-9.2 from each of these systems was tested against candidate substrates, including ascarosides and either MB-coenzyme A (CoA), MB-choline, or MB-carnitine. No enzymatic activity was detected using these substrates, suggesting that either the transmembrane domain is necessary for activity or that the correct substrates have not yet been identified. We showed that the purified CEST-9.2 from Sf9 cells is well-folded and dimeric, offering a potential starting point for future structural and mechanistic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.